TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 08, 2022 (Globe NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) (“ProMIS” or the “Company”), a biotechnology enterprise concentrated on the discovery and development of antibody therapeutics concentrating on misfolded proteins such as poisonous oligomers, implicated in the growth of neurodegenerative ailments, today announced that it has been given last acceptance from The Nasdaq Money Industry LLC (“Nasdaq”) to record its popular shares (the “Common Shares”) on Nasdaq. The Company’s Widespread Shares will begin buying and selling on Friday, July 8th, 2022, below the symbol “PMN”.
The Company’s Widespread Shares will continue to trade on the Toronto Inventory Trade (TSX) below the same image “PMN” (its present-day image). Concurrent with the listing of ProMIS’ Frequent Shares on Nasdaq, the Frequent Shares will stop to be quoted on the OTCQB.
Eugene Williams, Chairman and CEO of ProMIS, explained, “The listing of our stock on the Nasdaq represents a considerable milestone in our growth as a publicly traded corporation. Nasdaq is the leading worldwide inventory trade for life science and biotechnology organizations. We feel this listing will raise our visibility in the market, improve liquidity, broaden and diversify our shareholder foundation, and in the long run improve lengthy-phrase shareholder value. I would like to thank our shareholders for their guidance, as well as everybody whose challenging operate has resulted in producing ProMIS a member of the Nasdaq exchange. This transformative step will assist aid the continued progression of our pipeline of differentiated therapies concentrating on misfolded proteins in Alzheimer’s, ALS, and other conditions with important unmet will need.”
About ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a development stage biotechnology firm targeted on identifying and developing antibody therapeutics selectively targeting poisonous oligomers implicated in the advancement and development of neurodegenerative diseases, in specific Alzheimer’s disorder (Ad), amyotrophic lateral sclerosis (ALS) and Parkinson’s ailment (PD). The Company’s proprietary concentrate on discovery engine is dependent on the use of two complementary procedures. The Company applies its thermodynamic, computational discovery platform – ProMIS™ and Collective Coordinates – to forecast novel targets regarded as Condition Particular Epitopes on the molecular area of misfolded proteins. Working with this distinctive approach, the Firm is acquiring novel antibody therapeutics for Ad, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with workplaces in Cambridge, Massachusetts. ProMIS is shown on Nasdaq and the Toronto Stock Exchange less than the image PMN.
Visit us at www.promisneurosciences.com, abide by us on Twitter and LinkedIn
For Trader Relations please call:
Alpine Fairness Advisors
Nicholas Rigopulos, President
[email protected]
Tel. 617 901-0785
Particular information in this information launch constitutes forward-seeking statements and forward-searching info (collectively, ”forward-looking information”) within the that means of applicable securities legislation. In some conditions, but not necessarily in all situations, forward–wanting info can be determined by the use of ahead-searching terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, ”is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variants of these types of phrases and phrases or condition that sure steps, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to anticipations, projections or other characterizations of future situations or circumstances incorporate ahead-looking information. Specifically, this information launch has forward-searching information and facts relating to the continued trading of the Company’s Prevalent Shares on the TSX. Forward-wanting data is essentially primarily based on a quantity of thoughts, assumptions and estimates. Important aspects that could induce true results and money issue to vary materially from individuals indicated in the ahead-hunting details include, among the many others, the aspects talked about through the “Risk Factors” section of the Company’s Registration Statement on Kind 10 readily available on www.sec.gov and the Company’s most just lately submitted annual information form out there on www.SEDAR.com. Apart from as required by applicable securities regulations, the Organization undertakes no obligation to publicly update any forward-seeking data, whether or not created or oral, that may well be created from time to time, regardless of whether as a consequence of new information and facts, future developments or in any other case.
##
CBJ Newsmakers
